Replimune Group, Inc. (REPL) is a publicly traded Healthcare sector company. As of August 7, 2026, REPL trades at $12.01 with a market cap of $994.03M and a P/E ratio of -3.59. REPL moved -6.34% today. Year to date, REPL is +32.30%; over the trailing twelve months it is +103.48%. Its 52-week range spans $1.50 to $14.80. Analyst consensus is buy with an average price target of $14.75. Rallies surfaces REPL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for REPL, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $12.01 |
| Market Cap | $994.03M |
| P/E Ratio | -3.59 |
| EPS | $-3.38 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.80 |
| 52-Week Low | $1.50 |
| Volume | 6.25M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-313.94M |
| Gross Margin | 0.00% |
6 analysts cover REPL: 0 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $14.75.